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A case of a basal cell carcinoma (BCC) of the nictitating membrane (NM) in a
9-year-old female spayed dachshund is reported. Computed tomography and
resection of the NM followed by cryosurgery was performed. Although uncom-
mon, BCC should be considered as a differential diagnosis for tumors of the
NM.
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Introduction
Neoplasia of the conjunctiva, as well as of the nictitating
membrane (NM), is uncommon in the dog; however, the
following neoplasms have been reported: melanomas,
melanocytoma, adenocarcinomas, squamous cell carci-
nomas, mast cell tumors, papillomas, hemangiomas,
hemangiosarcomas, lymphomas, myoepitheliomas extra-
medullary plasmacytomas, canine transmissible venereal
tumors, malignant peripheral nerve sheath tumors, and
basal cell carcinoma [1–16]. A recent retrospective paper
studying 127 dogs with tumors of the NM showed that
the most common tumor was adenocarcinoma (85%) fol-
lowed by adenoma of the NM gland (14.2%) and squa-
mous cell carcinoma (0.8%) [15].
Basal cell tumors (BCT) represent a heterogeneous
group of epithelial neoplasms that arise without squa-
mous and adnexal differentiation [17]. BCTs are the most
common type of skin tumor in the cat and are less com-
mon in the dog [18–22]. Basal cell carcinoma (BCC) in
dogs, cats, and people is currently defined as a low-grade
neoplasm arising from the basal cells of either the inter-
follicular epidermis or the hair follicles and may represent
a neoplastic transformation of stem cells [23–26]. Primary
BCC of mucous membranes is extremely rare [27]. In
people, very few reports exist of primary BCC of the con-
junctiva or caruncle [28–35]. Basal cell carcinoma arising
from the NM is an uncommon finding in veterinary med-
icine, and there is a paucity of reports documenting BCC
in the NM, including a BCT of the NM in a horse [36].
A recent report presented histopathological and immuno-
histochemical features of atypical epithelial tumors of the
canine NM including two cases of basal cell adenocarci-
nomas [14]. This case report provides a detailed descrip-
tion of the clinical, imaging, histological, and
immunohistochemical characteristics of a basal cell carci-
noma from the NM in a dog.
Case Report
History and signalment
A 9-year-old female, spayed, long-haired Dachshund was
referred to the Ophthalmology Service at Auburn Univer-
sity College of Veterinary Medicine (AUCVM) following a
2- to 3-week history of bilateral mydriasis and ocular dis-
charge from the right eye (OD). The dog had been treated
with neomycin/polymyxin/dexamethasone ophthalmic
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ointment (q8 hr; Alcon Laboratories, Ft Worth, TX, USA)
for 1 week with a partial positive response.
Ophthalmic examination
A complete ophthalmic examination was performed on
both eyes (OU). Moderate blepharospasm and mild
mucoid discharge were detected OD. Vision was normal
OU (with normal menace and dazzle responses). Pupillary
light reflexes (direct and indirect) were present but mark-
edly decreased in both eyes due to severe iris atrophy.
Tear production, as determined by tear test (Schirmer
Tear Test Strips; Schering-Plough Animal Health, Kenil-
worth, NJ, USA), was 16 mm/min OD and 20 mm/min
OS. Diffuse illumination of the adnexa revealed no abnor-
malities OS, while severe chemosis and inflammation of
the palpebral conjunctiva and NM were noted OD.
Retraction of the right NM revealed an irregular, pink,
multilobulated mass affecting the bulbar, and medial
aspect of the NM (Fig. 1A). At that time, it was difficult
to determine whether the mass infiltrated the ventral
orbit.
Slit-lamp biomicroscopy (Kowa SL-14, Kowa Com-
pany, Ltd., Tokyo, Japan) was used for the examination
of the anterior segment. The cornea and anterior chamber
OU were grossly unremarkable. Fluorescein test (Akorn
Inc., Buffalo Grove, IL, USA) was negative OU. There
was nuclear sclerosis and severe iris atrophy in both eyes.
One drop of proparacaine 0.5% solution (Bausch & Lomb
Pharmaceuticals Inc., Tampa, FL, USA) was applied to
each eye. Intraocular pressures, obtained with applanation
tonometry (Tonopen XL; Reichert Technologies, Depew,
NY, USA), were 9 mmHg OD and 11 mmHg OS. The
posterior segment and funduscopy were normal in both
eyes.
Although palpation of mandibular lymph nodes was
normal, a fine needle aspirate from the right mandibular
lymph node was performed; the lymph node was
considered to be mildly reactive via cytologic evaluation.
No abnormalities were noted on the rest of the physical
examination. An incisional biopsy of the right NM mass
was also performed following application of one
drop of proparacaine 0.5% solution (Bausch & Lomb
Pharmaceuticals Inc., Tampa, FL, USA). The biopsy was
obtained using Westcott tenotomy scissors and was subse-
quently fixed in 10% neutral-buffered formalin (NBF).
The patient was discharged with neomycin/polymyxin/
bacitracin ophthalmic ointment (Akron, Inc., Lake Forest,
IL, USA) to be applied OD every 8 h until histopathology
results were received.
Histopathology from incisional biopsy
Incisional biopsy sections were of an unencapsulated,
well-demarcated, multilobular neoplastic mass composed
of basal cells seated within a moderately dense fibrovascu-
lar stroma. Based on the cellular morphology, the neo-
plasm was diagnosed as a presumptive basal cell tumor.
Due to the lack of natural borders and the size of the tis-
sue fragments, it was difficult to determine whether the
neoplasm represented a benign process such as a meibo-
mian epithelioma or a malignant process, such as a basal
cell carcinoma. There was no evidence of sebaceous or
squamous differentiation in the examined sections.
Anesthesia, imaging, and surgery
Based on the histopathologic diagnosis and potential neo-
plastic invasion of the orbit and globe, a computed
tomography (CT) was performed. The patient was
sedated with dexmedetomidine (10 lg/kg IM; Dexdomi-
tor, Zoetis, Florham Park, NJ, USA) and hydromor-
phone (0.1 mg/kg IM; West Ward, Eatontown, NJ, USA).
Transverse CT images of the head were obtained pre-
and postcontrast with 5.0-mm slices in bone and soft
algorithms. Dorsal images were obtained postcontrast
(A) (B)
Figure 1. (A) Image of the right eye at presentation. Note conjunctival hyperemia and irregular mass behind nictitating membrane. (B) Lateral
canthotomy allowing for exposure of NM and entirety of mass.
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with 3.0-mm slices and 1.0-mm slices through the region
of interest. CT imaging showed a relatively well-defined,
soft tissue attenuating, contrast enhancing, 1.1 9 2.0 9
1.6 cm ovoid mass in the cranioventral aspect of the right
orbit causing mild caudolateral displacement of the globe
(Fig. 2A and B). Invasion of orbital structures was not
observed. The retropharyngeal and mandibular lymph
nodes were within normal limits.
Based on the CT results, the decision was made to per-
form resection of the NM. Anesthetic induction was
achieved with propofol (4 mg/kg IV; Propoflo, Abbott
Animal Health, North Chicago, IL, USA) to effect. Gen-
eral anesthesia was maintained after endotracheal intuba-
tion with inhalant isoflurane 1–2% in oxygen (Isoflo;
Abbott Animal Health, North Chicago, IL, USA). After
surgical preparation of the ocular surface and adnexa, a
lateral canthotomy was performed to visualize and expose
the tumor (Fig. 1B). After exposing the tumor, the entire
NM and visible mass were resected followed by the appli-
cation of cryotherapy via a double freeze thaw method, as
an adjunctive therapy. The canthotomy incision was then
closed in two layers using 6-0 polyglactin 910 (Vicryl,
Ethicon; Johnson and Johnson, New Brunswick, NJ, USA)
and 5-0 nylon (Ethilon, Ethicon; Johnson and Johnson,
New Brunswick, NJ, USA).
The eye was treated postsurgically with neomycin/poly-
myxin/bacitracin OD q6 hr, diclofenac sodium 0.1% OD
q8 hr (Pack Pharmaceuticals, LLC, Buffalo Grove, IL,
USA), lubrication OD q6 hr (Lubrifresh PM; Major Phar-
maceuticals, MI, USA), oral carprofen (2.2 mg/kg PO
q12 hr for 10 days, Rimadyl tablets; Zoetis, Florham Park,
NJ, USA), and cephalexin (30 mg/kg PO q12 hr for
10 days, Cephalexin Capsules, Teva Pharmaceuticals USA,
Sellersville, PA, USA).
The mass and associated NM were fixed in 10% NBF
and submitted for histopathologic evaluation.
Final histopathology
The NM with a 2.4 9 1.5 9 1.4 cm multilobulated, well-
demarcated mass was received for histopathologic evalua-
tion. On cut section, the mass was pale-tan and firm with
foci of hemorrhage. Sections were composed of an unen-
capsulated, well-demarcated, multilobular, densely cellular
neoplastic mass that markedly expanded and effaced the
submucosa (Fig. 3). The mass was composed of sheets,
lobules, and trabeculae of peripheral basal cells seated
within a moderately dense fibrovascular stroma, as
(A) (B)
Figure 2. (A, B) Dorsal and transverse CT images of the skull. Note
well-defined, soft tissue attenuating 1 x 2 1.6 cm ovoid mass causing
caudodorsal displacement of globe.
Figure 3. Photomicrograph showing the subgross morphology of the
tumor. This is an unencapsulated, well-demarcated, multilobular,
densely cellular neoplastic mass that markedly expands and effaces
the submucosa. H&E. Bar = 500-lm.
Figure 4. Photomicrograph showing cellular organization within the
tumor. The neoplastic basal cells are arranged in sheets, lobules, and
trabeculae within a moderately dense fibrovascular stroma, H&E.
Bar = 100-lm.
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observed in the previous incisional biopsy (Fig. 4). The
majority of the neoplastic cells had scant amounts of eosi-
nophilic cytoplasm, ill-defined cytoplasmic borders, round
to ovoid euchromatic nuclei, and typically a single small
basophilic nucleolus (Fig. 5). Multifocally, clusters of neo-
plastic cells had moderate amounts of pale-eosinophilic,
finely granular or wispy cytoplasm, poorly delineated cel-
lular borders, ovoid or elongate nuclei, stippled chro-
matin, and a single prominent magenta nucleolus.
Anisocytosis and anisokaryosis were mild to moderate.
There were 25 mitotic figures in ten consecutive 400x
fields with occasional bizarre mitoses. Lymphoplasmacytic
aggregates and variably sized foci of hemorrhage and
necrosis were present throughout the mass with numer-
ous infiltrating foamy macrophages, often laden with
hemosiderin or cellular debris. Individual necrotic and
apoptotic cells were frequently observed. Along the
periphery of the mass, immediately adjacent to the NM
cartilage, was islands of basal cells that had a similar tinc-
torial quality as those cells described in the mass; how-
ever, these basal cells were occasionally arranged around
ductules (presumed nictitans gland ductules). The neo-
plastic cells had strong, diffuse cytoplasmic immunolabel-
ing for pan-cytokeratin (AE1/AE3; 1 in 50 dilution;
Dako, Carpinteria, CA), weak to moderate, often non-
specific immunolabeling for SMA (1 in 50 dilution;
Dako, Carpinteria, CA), and minimal, finely granular
cytoplasmic immunolabeling for Pax-5 (1 in 15 dilution;
Dako, Carpinteria, CA); the cells lacked immunolabeling
for Ber-EP4 (1 in 200 dilution; Dako, Carpinteria, CA)
and cytokeratin-18 (CK-18; 1 in 100 dilution; Abcam,
Cambridge, MA).
Outcome
The patient presented for evaluation 20 months after sur-
gery with no reported ocular disease or use of topical
medications (Fig. 6). A complete ophthalmic examination
was performed OU. Examination of the adnexa OD
revealed mild nasal entropion and absence of the NM.
Tear production, as determined by tear test (Schirmer
Tear Test Strips; Schering-Plough Animal Health, Kenil-
worth, NJ, USA), was 22 mm/min OD and 19 mm/min
OS. Biomicroscopy (Kowa SL-14, Kowa Company, Ltd.,
Tokyo, Japan) of the anterior segment showed minimal
superficial corneal neovascularization in the nasal quad-
rant OD, with negative fluorescein test (Akorn Inc., Buf-
falo Grove, IL, USA) OU. Tear breakup time was 12 sec
OD and 10 sec OS. Intraocular pressures, obtained with
rebound tonometry (TonoVet Icare Finland Oy, Hel-
sinki, Finland), were 12 mmHg OD and 13 mmHg OS.
The posterior segment and funduscopy were normal in
both eyes. The periorbital rim, mandibular lymph nodes,
and global retropulsion were normal with no evidence of
local recurrence 20 months after surgical excision.
Discussion
This case report describes the clinical, imaging, histologi-
cal, and immunohistochemical characteristics of a BCC of
the NM in a dog. Primary BCC of mucous membranes is
extremely rare and often arise in areas of long-term sun
Figure 5. Photomicrograph showing cellular morphology. In general,
the neoplastic cells have scant amounts of eosinophilic cytoplasm, ill-
defined cytoplasmic borders, round to ovoid euchromatic nuclei, and
typically a single small basophilic nucleolus. There is mild to moderate
anisocytosis and anisokaryosis with frequent mitoses (arrows). H&E.
Bar = 20-lm.
Figure 6. Image of the right eye 20 months following presentation.
Note lack of NM, slight nasal entropion and superficial nasal corneal
neovascularization and pigmentation.
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exposure [27]. In humans, very few reports exist of pri-
mary BCC of the conjunctiva or caruncle [28–35]. In the
veterinary literature, there was only one report of a basal
cell tumor involving the third eyelid of a horse [36].
More recently, a retrospective case report evaluated the
histopathologic and immunohistochemical features of
atypical epithelial tumors of NM in seven dogs where two
of the cases were diagnosed as basal cell adenocarcinoma
[14]. History, clinical findings, and follow-up were not
available for any of the cases.
Basal cell carcinomas (BCCs) occasionally may be diffi-
cult to distinguish from squamous cell carcinomas (SCCs)
that have large areas of basaloid differentiation. Although
they are typically readily classified on the basis of H&E
morphology, in human medicine, there are several
immunolabels that can be used to differentiate BCCs and
SCCs [37]. Epithelial membrane antigen (EMA) is a large
cell surface mucin glycoprotein expressed by most glandu-
lar and ductal epithelial cells and some hematopoietic
cells. BCCs tend to be negative for EMA, in contrast to
SCCs that have substantial EMA immunoreactivity. Ber-
EP4 is a monoclonal antibody that reliably labels epithe-
lial tissues but does not react with mesothelial cells [38].
Additionally, human BCCs are typically positive for this
marker, unlike SCCs. Smooth muscle actin (SMA) is a
monoclonal antibody that is intended for laboratory use
in the qualitative identification of smooth muscle actin
protein. SMA is documented to be expressed in a signifi-
cant number of human cutaneous BCTs; SCCs are gener-
ally negative for SMA. B-cell lymphoma 2 (BCL-2) is
another commonly used immunolabel in human pathol-
ogy that can help differentiate BCCs and SCCs. With this
marker, BCCs are typically diffusely positive while SCCs
generally lack immunoreactivity; however, focal positivity
has been reported [39]. In the present case, SMA and
Ber-EP4 immunolabels were utilized; however, results
were ambiguous, just as the immunolabels used in the
two previously reported by Miyazaki et al. [14]. The neo-
plasm was positive for SMA (expected with BCC) but
negative for Ber-EP4 (also expected to be positive in
BCC). Enigmatic SMA and Ber-EP4 immunolabeling in
this neoplasm may reflect a lack of appropriate cross-
reactivity in canine tissues or differences in protein
expression patterns between canine and human BCCs and
SCCs. Although immunolabeling in this case was incon-
clusive, the morphologic characteristics of this neoplasm
support the final diagnosis of basal cell carcinoma.
As previously described, primary BCC of the ocular
surface (including conjunctiva, NM, and caruncle) is
extremely rare in both human and veterinary ophthalmol-
ogy [14, 34, 36]. In humans, the main therapeutic
approach for primary BCC of the caruncle is complete
excision with tumor-free surgical margins. Adjuvant
therapy such as cryotherapy, radiotherapy, or chemother-
apy may be administered when deemed necessary, as in
patients with inadequate surgical margins, local recur-
rence, or those that had orbital invasion [35]. In the cur-
rent case, no signs of orbital invasion were noted on the
CT examination. Therefore, surgical excision of the NM
followed by cryotherapy was planned.
Prognosis for humans with primary BCC or the con-
junctiva or caruncle is generally good, although in some
cases, an unfavorable course is observed. Aggressiveness is
related mainly to local recurrence and invasion of the
orbit [34, 35]. Because long-term follow-up of veterinary
patients with BCC has not been documented, biologic
behavior of these tumors is unknown [14, 36]. In the pre-
sent case, no signs of local recurrence were observed
twenty months after surgery. However, in human oph-
thalmology, recurrences have been described even years
after complete excision, making long-term follow-up
mandatory [28, 34, 40].
In dogs, the NM gland produces 30–57% of the tear
film [41–43]. Removal of NM has been associated with
changes in the tear film pH, breakup time, and kerato-
conjunctival epithelium, as well as excessive exposure of
the ocular surface and secondary entropion with trichiasis
[44–46]. Close monitoring of the ocular surface should be
considered important during follow-up after NM
removal. In the present case, examination of the patient
revealed normal tear production and tear breakup time.
However, the patient developed slight medial entropion
and trichiasis that resulted in mild corneal neovasculariza-
tion. Because of this, lubrication was recommended (Gen-
teal Novartis, East Hanover, NJ).
To the authors’ knowledge, although previously
reported, this is the first detailed report of a BCC involv-
ing the NM of a dog that includes clinical presentation,
advanced imaging, diagnosis, treatment, and outcome.
Although uncommon, basal cell carcinoma should be
considered as a differential diagnosis for tumors of the
NM. These cases should be monitored long-term for
complications associated with removal of the NM as well
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